Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Recruiting · NCT06462365 · Interventional (participants receive a specific treatment) · Lead sponsor: Tr1X, Inc.
View the official record on ClinicalTrials.gov →Interventions studied
TRX103
What this trial is about
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)
- Males and Females Age ≥ 18 years.
- Weight of ≥ 35 Kg.
- Karnofsky performance status ≥ 70 %.
- Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.
- Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.
- Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.
- Have adequate organ function.
- Subjects \> 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score \< 5.
- Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.
Exclusion criteria
- Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.
- Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.
- HIV positive.
- Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.
- Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.
- Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and/or have not recovered from treatment related toxicities.
- Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.
- Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).
- Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.
Where it is running
5 locations listed across 5 US states.
- City of Hope - Duarte, California, United States
- Dana-Farber Cancer Institute - Boston, Massachusetts, United States
- University of Minnesota - Minneapolis, Minnesota, United States
- Memorial Sloan Kettering Cancer Center - New York, New York, United States
- Fred Hutchinson Cancer Center - Seattle, Washington, United States